18 years and hundreds of millions of dollars later, CVRx heart-failure device OK'd for U.S. market

Founded in 2001, Brooklyn Park-based medtech startup CVRx Inc. has raised hundreds of million of dollars in investor capital, but it hadn't been able to sell its heart-failure device in the U.S. Until now. CVRx announced late last week that the FDA had approved the Barostim Neo, CVRx's pacemaker-esque implantable device. It's been available in Europe for years. The Barostim Neo uses neuromodulation therapy, which means it stimulates the nervous system by using an electrode placed on th e neck's…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news